

REMARKS


As mentioned at page 16 of applicants' specification, compounds corresponding to compounds of applicants' genus, except that the N atom of the pyridyl ring is not in nitroxide form, are disclosed in related applications Serial No. 10/051,309, filed January 22, 2002, Serial No. 60/396,726, filed July 19, 2002, and Serial No. 10/622,117, filed July 18, 2003. It is believed that at least some of the compounds of the presently claimed genus are metabolites of compounds disclosed in Serial Nos. 10/051,309, 60/396,726, and 10/622,117.

In light of this metabolite relationship, the compound claims of the instant application are amended above to recite that the compounds are isolated. Support for this amendment can be found in the Examples. For example, Examples 1, 2 and 4 refer to concentrating the product *in vacuo*. Examples 2 and 3 describe purification by flash column chromatography. Example 4 refers to treating a crude product in a RediSep column.

In addition, claim 1 is amended to correct a typographical error in the definition of R⁴ by indicating that the alkyl portions of alkylamino or dialkylamino have independently 1 to 8 carbon atoms. Claim 38 is amended to correct the spelling of wherein. Also, composition claim 68 and method claims 70, 79, 81, and 82 have been rewritten in independent form. Finally, new claim 85 recites that the claimed compound is in the form of a substantially pure enantiomer. See, e.g., page 41, lines 1-10.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Brion P. Heaney, Reg. No. 32,542
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: MEMORY-35

Date: April 27, 2005